Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 194 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pancreatic Cancer Resectable Clear all
Terminated Phase 1 Interventional

Margin-Intense Combo Therapy in Pts w/Potentially Resectable Pancreatic Cancer

NCT01025882
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
gemcitabine hydrochloride, stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Jun 25, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

NCT02723331
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
Interventions
Nab paclitaxel, Gemcitabine
Drug
Lead sponsor
Academic Thoracic Oncology Medical Investigators Consortium
Industry
Eligibility
18 Years to 101 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • Tucson, Arizona • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jun 25, 2026, 9:43 AM EDT
Terminated No phase listed Observational

Identify microRNAs in Cachexia in Pancreatic Carcinoma

NCT05275075
View directory record Official record
Conditions
Resectable Pancreatic Adenocarcinoma
Interventions
Pancreatic cancer microRNA and messenger RNA expression.
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 25, 2026, 9:43 AM EDT
Active, not recruiting Phase 2 Interventional Results available

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

NCT04539808
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8, Stage III Pancreatic Cancer American Joint Committee on Cancer v8, Stage IV Pancreatic Cancer American Joint Committee on Cancer v8
Interventions
Capecitabine, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Losartan Potassium, Oxaliplatin, Radiation Therapy, Resection, Diagnostic Imaging, Biospecimen Collection, Gemcitabine, Nab paclitaxel
Drug · Radiation · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jun 25, 2026, 9:43 AM EDT
Terminated Early Phase 1 Interventional

Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas

NCT01276613
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Losartan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2019 · Synced Jun 25, 2026, 9:43 AM EDT
Completed Phase 1 Interventional

Chemoimmunotherapy and Radiation in Pancreatic Cancer

NCT01903083
View directory record Official record
Conditions
Locally Advanced Malignant Neoplasm
Interventions
Tadalafil, Gemcitabine, Radiation, Pancreaticoduodenectomy
Drug · Radiation · Procedure
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Jun 25, 2026, 9:43 AM EDT
Completed Phase 2 Interventional

Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer

NCT01298011
View directory record Official record
Conditions
Resectable Pancreatic Cancer
Interventions
Gemcitabine and Abraxane
Drug
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Scottsdale, Arizona • Grand Rapids, Michigan • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Jun 25, 2026, 9:43 AM EDT
Recruiting Phase 2 Interventional

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

NCT04858334
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Placebo Administration
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
451
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 304 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 25, 2026, 9:43 AM EDT
Completed Early Phase 1 Interventional

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

NCT01821612
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
Interventions
oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine
Drug · Radiation · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
La Jolla, California • Chicago, Illinois • Evanston, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Jun 25, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Results available

Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma

NCT01206296
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Intraperitoneal Gemcitabine
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jun 25, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02427841
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Interventions
Fluorouracil, Gemcitabine, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Nab-paclitaxel, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Jun 25, 2026, 9:43 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer

NCT02305186
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pembrolizumab, Neoadjuvant Chemoradiation
Drug · Radiation
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • Hartford, Connecticut • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Jun 25, 2026, 9:43 AM EDT
Completed Phase 1 Interventional Results available

Regional Chemotherapy in Locally Advanced Pancreatic Cancer: RECLAP Trial

NCT01294358
View directory record Official record
Conditions
Histologically or Cytologically Confirmed Pancreatic Ca, Unresectable or Borderline Resectable Pancreatic Ca
Interventions
Gemcitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jun 25, 2026, 9:43 AM EDT
Completed No phase listed Observational

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

NCT02685631
View directory record Official record
Conditions
Localized Non-Resectable Adult Liver Carcinoma
Interventions
Yttrium-90 Resin Microspheres
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
42
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Jun 25, 2026, 9:43 AM EDT
Not listed Phase 2 Interventional

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT01676259
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Interventions
siG12D-LODER, Gemcitabine+nab-Paclitaxel, Folfirinox
Drug
Lead sponsor
Silenseed Ltd
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Hackensack, New Jersey • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Jun 25, 2026, 9:43 AM EDT
Active, not recruiting Phase 1 Interventional

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

NCT05209074
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
Interventions
Ivosidenib, mFOLFIRINOX
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jun 25, 2026, 9:43 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer

NCT00557492
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
Drug · Radiation
Lead sponsor
Amer Zureikat
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Jun 25, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma

NCT03099265
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
neoadjuvant mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Jun 25, 2026, 9:43 AM EDT
Active, not recruiting Phase 2 Interventional

Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer

NCT03523312
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Hypofractionated ablative IMRT (HFA-IMRT), capecitabine
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 25, 2026, 9:43 AM EDT
Terminated Phase 3 Interventional

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

NCT01836432
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
Interventions
FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation, Gemcitabine, Capecitabine, Nab-Paclitaxel
Drug · Biological · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
32
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Jun 25, 2026, 9:43 AM EDT
Recruiting Phase 2 Interventional

Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer

NCT06605430
View directory record Official record
Conditions
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic, Colorectal Cancer Metastatic
Interventions
Medical Cannabis
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jun 25, 2026, 9:43 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy

NCT00766636
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Radiation Therapy, Erlotinib, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Jun 25, 2026, 9:43 AM EDT
Not listed Early Phase 1 Interventional

A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer

NCT02707315
View directory record Official record
Conditions
Pancreas Cancer, Pancreatic Cancer, Adenocarcinoma of the Pancreas, Pancreas Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions
Gemcitabine, Stereotactic Radiosurgery
Drug · Radiation
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Jun 25, 2026, 9:43 AM EDT
Recruiting Not applicable Interventional

Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery

NCT06731998
View directory record Official record
Conditions
Oncologic Surgery, Cancer, Cancer Surgery, Hepatic Cancer, Gastric (Cardia, Body) Cancer, Biliary Tract Cancer, Pancreatic Cancer Resectable, Gynecologic Cancers, Gastrointestinal Cancers, Colorectal Cancer, Minimally Invasive Surgical Procedures
Interventions
Local Anesthesia, Laparoscopic Transversus Abdominis Plane block
Procedure
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 89 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Jun 25, 2026, 9:43 AM EDT